I have always been drawn to non-traditional health care provider roles and the possibilities to expand the clinical boundaries of the profession of pharmacy. Being a practitioner in cardiac transplantation and cardiology allows me to work across the spectrum of patient care — acute care, chronic conditions, end-of-life. I love to work through the challenges of complex diseases and see the results of my interventions realized in excellent patient outcomes and an improved quality of life.
Dr. Glen Pearson obtained a Bachelor of Science degree in Biology from the University of Western Ontario and both his Bachelor of Science in Pharmacy (Cum Laude) and Doctor of Pharmacy (Cum Laude) degrees from the Philadelphia College of Pharmacy & Science. He was recruited to the University of Alberta in 2001.
Leadership and Collaborations:
Dr. Pearson is the co-director of the Cardiac Transplant Clinic and associate chair of the Health Research Ethics Board (Biomedical and Health Panel). He is a member of the Expert Committee on Drug Evaluation and Therapeutics for Alberta Health. Dr. Pearson is an active member of the Canadian Cardiology Pharmacists Network and the Canadian Cardiovascular Society (CCS). He has been a member of the CCS Canadian Dyslipidemia Guidelines primary panel since 2009 and is currently the Chair for the 2019 CCS Dyslipidemia Guidelines update. He was a primary panel member of the CCS 2018 CCS Position Statement on Familial Hypercholesterolemia (FH) and a member of the new FH Canada Registry practitioner initiative. He is also a primary member of the Canadian Working Group for the Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance.
He is a former president of both the Canadian Society of Hospital Pharmacists and the Canadian College of Clinical Pharmacy. He has been recognized for his both his clinical and leadership contributions thorough the receipt of numerous awards, including: the M.J. Houston Pharmacist of the Year Award from Alberta College of Pharmacists and the Alberta Pharmacists’ Association (2008), Alberta Pharmacy Centennial Award of Distinction (2011), APEX Partners in Practice Award for collaborative efforts to optimize patient care and safety in the University of Alberta/Mazankowski Alberta Heart Institute Cardiac Transplant Team (2011), Canadian Society of Hospital Pharmacists Pharmacotherapy Best Practices Award (2012/13), and a special recognition in 2008 for the achievement in becoming one of the first fifteen pharmacists in Canada to be granted additional prescribing authorization. He has also been conferred recognition with fellowship status in both the Canadian Society of Hospital Pharmacists and the Canadian Cardiovascular Society.
Global Edmonton Interview: Guidebook for Pharmacists on Diabetes Management: https://vimeo.com/107924655
Dr. Pearson currently teaches in the Cardio-Renal Block of the first Medical Practice course for medical and dental students. He also provides a number of lectures in cardiovascular pharmacotherapeutics to the both the undergraduate and graduate health professions students at the University of Alberta. He supervises post-doctoral (PharmD) students in clinical rotations (form UBC, UofT, and UofA) and has established clinical fellowship programs in ambulatory cardiovascular practice and multi-organ transplant practice through the Department of Medicine at the University of Alberta. Recently, he has co-developed the first Canadian advanced specialty residency program in Cardiology (PGY2-Cardiology) in collaboration with the Division of Cardiology and Alberta Health Services.
In addition to Dr. Pearson’s clinical research focused on assessing therapies, screening, diagnoses and care for cardiac and such associated conditions as cholesterol, he studies the role of pharmacists in patient disease management. A 2016 study Pearson led showed a three-fold increase in patients meeting their cholesterol level targets when pharmacists prescribed medications, ordered tests and explained test results. The study results were published in the Canadian Pharmacists Journal. He is author or co-author of publications resulting from numerous research projects including studies of familial hypercholesterolemia, published in the journal of the College of Family Physicians of Canada, of lipid-lowering agents published in the Canadian Journal of Cardiology, and of the evolving profession of pharmacy published in the Canadian Medical Association Journal. He was involved in the 2018 update to the Canadian Cardiovascular Harmonized National Guidelines Endeavour for the prevention and management of cardiovascular disease in primary care.
Cardiac Transplant, Cardiovascular Risk Reduction, CV surgery, Dyslipidemia, Outcomes Research, Pharmacotherapy
Berresheim M, Barry AR, Norris CM, Koshman SL, Nagendran J, Pearson GJ. Real-life Practice in the Management of New-onset Postoperative Atrial Fibrillation Early After Cardiac Surgery. Curr Res Cardiol 2015;2(2):73-76.
Butler CR, Savu A, Bakal JA, Toma M, Thompson R, Chow K, Wang H, Kim DH, Mengel M, Haykowsky M, Pearson GJ, Kaul P, Paterson I. Correlation of cardiovascular magnetic resonance imaging findings and endomyocardial biopsy results in patients undergoing screening for heart transplant rejection. J Heart Lung Transplant 2015;34(5):643-50.
Mancini GB, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, Gupta M, Hegele RA, Ng D, Pearson GJ, Pope J, Tashakkor AY. Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016). Can J Cardiol 2016;32(7 Suppl):S35-S65.
Anderson TJ, Grégoire J, Pearson GJ, et al. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for Prevention of Cardiovascular Disease in the Adult. Can J Cardiol 2016;32:1263-1282.
Turgeon RD, Pearson GJ, Graham MM. Pharmacological Treatment of Patients with Myocardial Ischemia with No Obstructive Coronary Artery Disease (INOCA). Am J Cardiology 2018;121:888-95.
Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update. Tobe S, Stone JA, Anderson T, Bacon S, Cheng AYY, Daskalopoulou, Ezekowitz JA, Gregoire J, Gubitz G, Jain R, Keshavjee K, Lindsay P, L’Abbé M, Lau DW, Leiter LA, O’Meara E. Pearson GJ, Rabi DM, Sherifali D, Selby P, Tu JV, Wharton S, Walker KM, Hua-Stewart D H, Liu PP. CMAJ 2018; October 9;190:E1192-206.
Turgeon RD, Tsuyuki RT, Gyenes G, Pearson GJ. Cardiovascular efficacy and safety of PCSK9-inhibitors: Systematic review and meta-analysis including the ODYSSEY Outcomes trial. Can J Cardiol 2018; 32:1600-1605.
Brunham LR, Ruel I, Aljenedil S, Rivière JB, Baass A, Tu JV, Mancini GBJ, Raggi P, Gupta, Couture P, Pearson GJ, Bergeron J, Francis GA, McCrindle BW, Morrison K, St-Pierre J, Henderson M, Hegele RA, Genest J. Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018. Can J Cardiol 2018; 32:1553-63.
Hong J, Turgeon RD, Pearson GJ. Switching to Clopidogrel in Patients with Acute Coronary Syndrome Initially Treated with Prasugrel or Ticagrelor: Systematic Review and Meta-Analysis. Ann Pharmacother 2019;53(10):997-1004.
Turgeon RD, Koshman SL, Youngson E, Pearson GJ. Association between hemoglobin A1c and major adverse coronary events in patients with diabetes following coronary artery bypass surgery. Pharmacother 2020;40(2):116-124.